Aragen Bioscience
Aragen Bioscience is a private CRDMO providing integrated biologics development and manufacturing services, from cell line development through GMP production, using proprietary CHO-based platforms. It serves 400+ biotech, pharma, biosimilar, animal health, and academic clients from California R&D and Bengaluru manufacturing sites.
- Company typePrivate
- Founded2006
- HeadquartersMorgan Hill, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Aragen Bioscience does
Aragen Bioscience is a privately-held contract research, development, and manufacturing organization (CRDMO) specializing in biologics, operating as a division of Aragen Life Sciences. Founded in 2006 and headquartered in Morgan Hill, California, the company provides integrated services spanning cell line development, process development, bioproduction, analytical characterization, antibody discovery, and GLP-compliant preclinical efficacy testing. Its proprietary technology platforms — CHOMax™ (launched January 2026) and RapTr2022 (launched August 2023) — center on CHO (Chinese Hamster Ovary) cell line development using CHO-DG44 and CHO-GS lines with proprietary expression vectors, refined across more than 200 programs. The platforms target DNA-to-IND-enabling clinical supply timelines of approximately 10 months, with reported titers of 8 g/L at clonal stage and up to 27 g/L after process optimization, offered on a royalty-free basis to sponsors.
The company serves a diversified customer base of 400+ clients across biotech, biosimilars, animal health, and government/academic research segments, including 7 of the top 10 global pharmaceutical companies. Revenue is generated through project-based fee-for-service contracts and integrated managed-service programs spanning cell line development through GMP manufacturing. Distribution is direct enterprise sales with no channel or reseller model; go-to-market includes active participation in major industry conferences (BIO, PEGS Boston, CPHI, IPF Summit, DCAT) and a content-driven marketing approach.
Aragen operates a dual-hub model with R&D and early development at its Morgan Hill campus and biologics manufacturing at a new Bengaluru, India facility built through a $30M investment in wholly-owned subsidiary Aragen Biologics Pvt Ltd, operationalized in March 2024 with single-use bioreactor capacity from 50L to 2000L and annual capacity of 60–70 batches at 2KL scale. The organization employs approximately 5,000 people globally, including 450+ PhD-qualified scientists across six sites, and has completed 222 regulatory and client audits and 86+ global regulatory filings. The group is led by Manni Kantipudi (CEO, Aragen Life Sciences) and Subodh Deshmukh (CEO, Aragen Biologics).
Aragen Bioscience firmographics
Firmographics- Name
- Aragen Bioscience
- Legal name
- Aragen Life Sciences Ltd. and Aragen Biosciences Inc.
- Website
- https://aragenbio.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Aragen Bioscience is a private CRDMO providing integrated biologics development and manufacturing services, from cell line development through GMP production, using proprietary CHO-based platforms. It serves 400+ biotech, pharma, biosimilar, animal health, and academic clients from California R&D and Bengaluru manufacturing sites.
- Ownership category
- akta.pro rank
Aragen Bioscience industry classification
Industry- Product category
- Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO)
- NAICS
- Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Aragen Bioscience is headquartered
LocationHeadquarters
- HQ city
- Morgan Hill
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aragen Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Services: Fee-for-service contract research including cell line development, process development, analytical services, and preclinical efficacy testing. Revenue generated through project-based contracts with milestones and deliverables.
- Contract Manufacturing Services: GMP manufacturing services for biologics including monoclonal antibodies, therapeutic proteins, and fusion proteins. Manufacturing capacity spans from 50L to 2000L single-use bioreactors.
- Integrated Gene-to-GMP Programs: Comprehensive integrated programs from DNA through IND-enabling clinical supply, combining development and manufacturing services under unified project management.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Aragen Bioscience product offering
Product offeringCore offering
Aragen Bioscience is a contract research, development, and manufacturing organization (CRDMO) providing biologics services from cell line development through GMP manufacturing, plus preclinical efficacy testing across multiple therapeutic areas. Its offerings include CHO-based cell line development (CHOMax™ and RapTr2022 platforms), protein expression and purification, analytical and bioanalytical services, process development, GMP drug substance manufacturing (50L to 2,000L single-use bioreactors), antibody discovery, and preclinical in vivo efficacy studies in fibrosis, oncology, immunology, infectious, and respiratory diseases.
Differentiator
Problem solved
Functional benefit
Brands
- RapTr: Accelerated biologics development platform launched in 2023, designed to reduce development timelines by 33%
- CHOMax
Products and services
- Cell Line Development
Quantifiable outcome
- DNA to IND-enabling clinical supply in ~10 months for standard IgG mAbs
- +4 more outcomes
Companies that use Aragen Bioscience
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles5 records
Aragen Bioscience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Aragen Bioscience partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Renaissance PharmacoreOngoing strategic collaboration for manufacturing Renaissance Pharma's FDA Fast Track designated monoclonal antibody Daretabart (anti-GD2 for high-risk neuroblastoma). Aragen developed cell line and initial process at Morgan Hill, with GMP manufacturing transitioning to Bengaluru facility.
- GetingecoreSuccessful validation of Getinge's Single-Use Production Reactors (SUPR) for large-scale recombinant antibody production. Aragen uses Getinge's 50L and 250L SUPRs at Morgan Hill facility for preclinical and toxicology production. Getinge benefits from customer validation data for their SUPR platform.
- FAR BiotechcoreCollaboration to advance preclinical programs in neurodegeneration. Aragen deploys its integrated drug discovery platform to help FAR Biotech advance its small molecule program. FAR Biotech provides AI-driven computational drug discovery capabilities with novel molecules for hard-to-drug targets.
Scale indicators14 records
Recent moves8 records
Expansion highlights5 records
Aragen Bioscience competitors and assessment
Company assessmentDirect peers
- Lonza Biologics: Lonza is the largest global biologics CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of mAbs and recombinant proteins — directly overlapping with Aragen's CHOMax and GMP manufacturing services for the same sponsor base.
- AGC Biologics: AGC Biologics is a mid-tier global biologics CDMO offering mammalian cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, comparable in scale and service scope to Aragen.
- KBI Biologics: KBI Biologics is a mid-size CDMO providing mammalian cell line development, process development, analytical services, and GMP manufacturing of mAbs and recombinant proteins — a comparable integrated biologics services provider.
- Rentschler Biopharma: Rentschler is a privately held European biologics CDMO offering cell line development, process development, and GMP manufacturing of mAbs and recombinant proteins, overlapping directly with Aragen's integrated gene-to-GMP biologics platform.
- WuXi Biologics: WuXi Biologics is a leading biologics CRDMO offering cell line development, process development, and GMP manufacturing of mAbs, bispecifics, and recombinant proteins with a global dual-hub model similar to Aragen's California/India footprint.
- Catalent (Novo Holdings): Catalent is a global CDMO with biologics cell line, process development, and GMP manufacturing services for mAbs and recombinant proteins, directly competing with Aragen for biotech and pharma integrated development programs.
- Samsung Biologics: Samsung Biologics operates very large-scale mammalian GMP manufacturing (multi-KL bioreactors) for mAbs and recombinant proteins, plus integrated development services, making it a direct competitor for sponsors seeking gene-to-commercial biologics CDMO capacity.
- Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth is a major CDMO offering mammalian cell line development, process development, and large-scale GMP manufacturing of biologics — a direct competitor in Aragen's CHO-based integrated services segment.
- Boehringer Ingelheim BioXcellence: BioXcellence is Boehringer Ingelheim's contract manufacturing arm offering process development and large-scale GMP manufacturing of mAbs and recombinant proteins, competing for the same biopharma and biotech sponsor base as Aragen.
Broad incumbents
- Charles River Laboratories: Charles River is a large preclinical CRO/CDMO with biologics cell line development, manufacturing, and preclinical efficacy testing services spanning discovery through GMP — relevant to Aragen's preclinical and biologics services portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Aragen Bioscience social profiles
Digital presenceAragen Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aragen Bioscience leadership team
Management profileNumber of profiles
Profiles12 records
Aragen Bioscience subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aragen Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aragen Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aragen Bioscience
What does Aragen Bioscience do?
Aragen Bioscience is a contract research, development, and manufacturing organization (CRDMO) providing biologics services from cell line development through GMP manufacturing, plus preclinical efficacy testing across multiple therapeutic areas. Its offerings include CHO-based cell line development (CHOMax™ and RapTr2022 platforms), protein expression and purification, analytical and bioanalytical services, process development, GMP drug substance manufacturing (50L to 2,000L single-use bioreactors), antibody discovery, and preclinical in vivo efficacy studies in fibrosis, oncology, immunology, infectious, and respiratory diseases.
Is Aragen Bioscience a public or private company?
Aragen Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Aragen Bioscience founded?
Aragen Bioscience was founded in 2006. It employs 1,001 to 5,000 people.
Where is Aragen Bioscience based?
Aragen Bioscience is headquartered in Morgan Hill, United States, in the North America region.
How does Aragen Bioscience make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are contract Manufacturing Services and integrated Gene-to-GMP Programs.
Who are Aragen Bioscience's main competitors?
Direct peers on record are Lonza Biologics, AGC Biologics, KBI Biologics, Rentschler Biopharma, WuXi Biologics, Catalent (Novo Holdings), Samsung Biologics, Fujifilm Diosynth Biotechnologies and Boehringer Ingelheim BioXcellence. Charles River Laboratories is listed as a broad incumbent.
Does Aragen Bioscience have an API?
No public API is recorded for Aragen Bioscience.
What industry is Aragen Bioscience in?
Aragen Bioscience's product category is Contract Research, Development, and Manufacturing Services (Biologics CRO/CRDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.